SEARCH

SEARCH BY CITATION

References

  • 1
    Fernandez NC,Lozier A,Flament C,Ricciardi-Castagnoli P,Bellet D,Suter M,Perricaudet M,Tursz T,Maraskovsky E,Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5: 40511.
  • 2
    Gerosa F,Baldani-Guerra B,Nisii C,Marchesini V,Carra G,Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002; 195: 32733.
  • 3
    Piccioli D,Sbrana S,Melandri E,Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002; 195: 33541.
  • 4
    Ferlazzo G,Tsang ML,Moretta L,Melioli G,Steinman RM,Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002; 195: 34351.
  • 5
    Borg C,Jalil A,Laderach D,Maruyama K,Wakasugi H,Charrier S,Ryffel B,Cambi A,Figdor C,Vainchenker W,Galy A,Caignard A, et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 2004; 104: 326775.
  • 6
    Siegal FP,Kadowaki N,Shodell M,Fitzgerald-Bocarsly PA,Shah K,Ho S,Antonenko S,Liu YJ. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284: 18357.
  • 7
    Palucka K,Banchereau J. Linking innate and adaptive immunity. Nat Med 1999; 5: 86870.
  • 8
    Caux C,Massacrier C,Vanbervliet B,Dubois B,Van Kooten C,Durand I,Banchereau J. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180: 126372.
  • 9
    Kikuchi T,Moore MA,Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 2000; 96: 919.
  • 10
    Kikuchi T,Miyazawa N,Moore MA,Crystal RG. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res 2000; 60: 63915.
  • 11
    Miyazaki A,Sato N,Takahashi S,Sasaki A,Kohama G,Yamaguchi A,Yagihashi A,Kikuchi K. Cytotoxicity of histocompatibility leukocyte antigen-DR8-restricted CD4 killer T cells against human autologous squamous cell carcinoma. Jpn J Cancer Res 1997; 88: 1917.
  • 12
    Nakamura T,Sato K,Hamada H. Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors. Hum Gene Ther 2002; 13: 61326.
  • 13
    Yoshida Y,Sadata A,Zhang W,Saito K,Shinoura N,Hamada H. Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. Hum Gene Ther 1998; 9: 250315.
  • 14
    Kanegae Y,Lee G,Sato Y,Tanaka M,Nakai M,Sakaki T,Sugano S,Saito I. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific cre recombinase. Nucleic Acids Res 1995; 23: 381621.
  • 15
    Nyberg-Hoffman C,Shabram P,Li W,Giroux D,Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med 1997; 3: 80811.
  • 16
    Uchida H,Tanaka T,Sasaki K,Kato K,Dehari H,Ito Y,Kobune M,Miyagishi M,Taira K,Tahara H,Hamada H. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 2004; 10: 16271.
  • 17
    Testi R,Phillips JH,Lanier LL. T cell activation via Leu-23 (CD69). J Immunol 1989; 143: 11238.
  • 18
    Nagler A,Lanier LL,Cwirla S,Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989; 143: 318391.
  • 19
    Ellis TM,Fisher RI. Functional heterogeneity of Leu 19“bright”+ and Leu 19“dim”+ lymphokine-activated killer cells. J Immunol 1989; 142: 294954.
  • 20
    Zamai L,Ahmad M,Bennett IM,Azzoni L,Alnemri ES,Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1998; 188: 237580.
  • 21
    Smyth MJ,Cretney E,Takeda K,Wiltrout RH,Sedger LM,Kayagaki N,Yagita H,Okumura K. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001; 193: 66170.
  • 22
    Takeda K,Hayakawa Y,Smyth MJ,Kayagaki N,Yamaguchi N,Kakuta S,Iwakura Y,Yagita H,Okumura K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001; 7: 94100.
  • 23
    Tsutsui H,Nakanishi K,Matsui K,Higashino K,Okamura H,Miyazawa Y,Kaneda K. IFN-γ-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 1996; 157: 396773.
  • 24
    Eischen CM,Schilling JD,Lynch DH,Krammer PH,Leibson PJ. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J Immunol 1996; 156: 26939.
  • 25
    Albert ML,Sauter B,Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 869.
  • 26
    Mazzei GJ,Edgerton MD,Losberger C,Lecoanet-Henchoz S,Graber P,Durandy A,Gauchat JF,Bernard A,Allet B,Bonnefoy JY. Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995; 270: 70258.
  • 27
    Pietravalle F,Lecoanet-Henchoz S,Blasey H,Aubry JP,Elson G,Edgerton MD,Bonnefoy JY,Gauchat JF. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem 1996; 271: 59657.
  • 28
    Kato K,Santana-Sahagun E,Rassenti LZ,Weisman MH,Tamura N,Kobayahsi S,Hashimoto H,Kipps TJ. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999; 104: 94755.
  • 29
    Ellis TM,McKenzie RS,Simms PE,Helfrich BA,Fisher RI. Induction of human lymphokine-activated killer cells by IFN-α and IFN-γ. J Immunol 1989; 143: 42826.
  • 30
    Garrido F,Ruiz-Cabello F,Cabrera T,Perez-Villar JJ,Lopez-Botet M,Duggan-Keen M,Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18: 8995.
  • 31
    Romero JM,Jimenez P,Cabrera T,Cozar JM,Pedrinaci S,Tallada M,Garrido F,Ruiz-Cabello F. Coordinated downregulation of the antigen presentation machinery and HLA class I/β2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer 2005; 113: 60510.
  • 32
    Pan G,O'Rourke K,Chinnaiyan AM,Gentz R,Ebner R,Ni J,Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 1113.
  • 33
    Walczak H,Degli-Esposti MA,Johnson RS,Smolak PJ,Waugh JY,Boiani N,Timour MS,Gerhart MJ,Schooley KA,Smith CA,Goodwin RG,Rauch CT. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16: 538697.
  • 34
    Nagane M,Pan G,Weddle JJ,Dixit VM,Cavenee WK,Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000; 60: 84753.
  • 35
    Sheikh MS,Huang Y,Fernandez-Salas EA,El-Deirv WS,Friess H,Amundson S,Yin J,Meltzer SJ,Holbrook NJ,Fornace AJ,Jr. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene 1999; 18: 41539.
  • 36
    Schneider P,Tschopp J. Apoptosis induced by death receptors. Pharm Acta Helv 2000; 74: 2816.
  • 37
    Sedger LM,Shows DM,Blanton RA,Peschon JJ,Goodwin RG,Cosman D,Wiley SR. IFN-γ mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 1999; 163: 9206.
  • 38
    Merchant MS,Yang X,Melchionda F,Romero M,Klein R,Thiele CJ,Tsokos M,Kontny HU,Mackall CL. Interferon γ enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res 2004; 64: 834956.